Scholar Rock
Develops anti-myostatin antibodies for spinal muscular atrophy and other neuromuscular diseases.
$57.80
After-hours close0.00 (0.00%)
At close$57.80(−2.46%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 120.35%Insiders 9.60%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 119.83M · Float 96.39M · 80.4% free float
Institutions13F, as of Jun 30, 2026
316 holders · 144.21M shares · 59 new positions · 190 increased · 83 reduced · 28 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 18.00M | 15.02% | +752.1K | Aug 13, 2026 |
| Siren, L.L.C. | 9.58M | 7.99% | −1.25M | Aug 13, 2026 |
| BlackRock, Inc. | 9.49M | 7.92% | +2.02M | Aug 7, 2026 |
| Samsara Biocapital, LLC | 6.90M | 5.76% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.79M | 5.67% | +588.2K | Aug 14, 2026 |
| Wellington Management Group LLP | 6.73M | 5.61% | +9.4K | Aug 14, 2026 |
| Orbis Allan Gray Ltd | 5.93M | 4.95% | +1.75M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.77M | 3.98% | +876.5K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 14.11M | 13G | Feb 12, 2025 ↗ |
| Invus Public Equities, L.P. | 11.40% | 10.83M | 13G | Feb 12, 2025 ↗ |
| Redmile Group, LLC | 7.60% | 9.07M | 13G | May 15, 2026 ↗ |
| Srinivas Akkarajuincl. Samsara Opportunity Fund GP, LLC, Samsara Opportunity Fund, L.P. +2 more | 7.20% | 6.99M | 13D | Oct 7, 2025 ↗ |
| Wellington Management Group LLP | 5.60% | 5.76M | 13G | Feb 10, 2026 ↗ |
| T. Rowe Price Associates, Inc. | 5.40% | 6.21M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Invus Global Management, LLC | 10 percent owner | 10.83M | 9.03% | Feb 6, 2026 |
| Srinivas Akkaraju | director | 6.40M | 5.34% | Jun 8, 2026 |
| David Hallal | director, officer: Chief Executive Officer | 1.64M | 1.37% | Apr 20, 2026 |
| Akshay Vaishnaw | director, officer: President of R&D | 630.5K | 0.53% | Apr 20, 2026 |
| Keith Woods | officer: Chief Operating Officer | 620.1K | 0.52% | Apr 20, 2026 |
| Vikas Sinha | officer: Chief Financial Officer | 619.9K | 0.52% | Apr 20, 2026 |
| Jay T. Backstrom | director, officer: CHIEF EXECUTIVE OFFICER | 425.6K | 0.36% | Mar 12, 2025 |
| Junlin Ho | officer: GENERAL COUNSEL | 241.5K | 0.20% | Feb 19, 2026 |
| Caryn Parlavecchio | officer: CHRO | 169.1K | 0.14% | Feb 19, 2026 |
| Jing L. Marantz | officer: CHIEF MEDICAL OFFICER | 126.0K | 0.11% | Feb 19, 2026 |
8 ten-percent owners hold 41.41M shares by Form 4, outside the officers-and-directors figure above · 7 people have not refiled in the last 18 months (9.81M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 1, 2026 | Katie Pengdirector | Sale · 3 lots | 5,446 | $53.88 | 34,301 |
| Jul 1, 2026 | Joshua Reeddirector | Sale · 2 lots | 3,053 | $53.74 | 19,518 |
| Jul 1, 2026 | Kristina Burowdirector | Sale · 2 lots | 3,053 | $53.74 | 114,657 |
| Jul 1, 2026 | Michael Gilmandirector | Sale · 3 lots | 2,544 | $53.87 | 59,511 |
| Jul 1, 2026 | Jeffrey S. Flierdirector | Sale · 3 lots | 3,053 | $53.88 | 27,856 |
| Apr 16, 2026 | David Hallaldirector, officer: Chief Executive Officer | Sale | 30,615 | $49.57 | 1,639,034 |
| Apr 16, 2026 | Vikas Sinhaofficer: Chief Financial Officer | Sale | 10,410 | $49.57 | 619,856 |
| Apr 16, 2026 | Akshay Vaishnawdirector, officer: President of R&D | Sale | 12,246 | $49.57 | 630,542 |
| Apr 16, 2026 | Keith Woodsofficer: Chief Operating Officer | Sale | 10,220 | $49.57 | 620,055 |
| Feb 23, 2026 | Mo Qatananiofficer: CHIEF SCIENTIFIC OFFICER | Sale · 3 lots | 8,484 | $47.07 | 98,445 |
CongressHouse and Senate disclosures
Not reported.